Unmet need in diabetic nephropathy: failed drugs or trials?

The Lancet Diabetes and Endocrinology

Volumn 4, Issue 8, 2016, Pages 638-640

  de Zeeuw, Dick ^a   Heerspink, Hiddo J L ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALISKIREN; AVOSENTAN; EMPAGLIFLOZIN; FINERENONE; HEMOGLOBIN; IRBESARTAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; POTASSIUM; SULODEXIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NEW DRUG;

ALBUMINURIA; CLINICAL TRIAL (TOPIC); DIABETIC NEPHROPATHY; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; ESTIMATED GLOMERULAR FILTRATION RATE; HEALTH CARE NEED; HEART FAILURE; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OUTCOME ASSESSMENT; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION; SODIUM RETENTION; TREATMENT RESPONSE; MORTALITY; PROCEDURES;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUGS, INVESTIGATIONAL; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 84965028768     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(16)30045-6     Document Type: Note

References (15)

1. 1 Brenner, BM, Cooper, ME, de Zeeuw, D, et al., for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001), 861–869.
2. 2 Lewis, EJ, Hunsicker, LG, Clarke, WR, et al., for the Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001), 851–860.
3. 3 de Zeeuw, D, Remuzzi, G, Parving, HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 65 (2004), 2309–2320.
4. 4 Keane, WF, Brenner, BM, de Zeeuw, D, et al., for the RENAAL Study Investigators. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 63 (2003), 1499–1507.
5. 5 Fried, LF, Emanuele, N, Zhang, JH, et al., for the VA NEPHRON-D Investigators. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369 (2013), 1892–1903.
6. 6 Parving, HH, Brenner, BM, McMurray, JJ, et al., for the ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367 (2012), 2204–2213.
7. 7 Pfeffer, MA, Burdmann, EA, Chen, CY, et al., for the TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361 (2009), 2019–2032.
8. 8 Packham, DK, Wolfe, R, Reutens, AT, et al., for the Collaborative Study Group. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol 23 (2012), 123–130.
9. 9 Mann, JF, Green, D, Jamerson, K, et al., for the ASCEND Study Group. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 21 (2010), 527–535.
10. 10 de Zeeuw, D, Akizawa, T, Audhya, P, et al., for the BEACON Trial Investigators. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 369 (2013), 2492–2503.
11. 11 Solomon, SD, Uno, H, Lewis, EF, et al., for the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 363 (2010), 1146–1155.
12. 12 Heerspink, HJ, Ninomiya, T, Persson, F, et al. Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial. Diabetes Obes Metab 18 (2016), 169–177.
13. 13 Chin, MP, Wrolstad, D, Bakris, GL, et al. Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. J Card Fail 20 (2014), 953–958.
14. 14 de Zeeuw, D, Parving, H-H, Coll, B, Andress, DL, Brennan, JJ, for the SONAR Steering Committee. Study Of diabetic Nephropathy with AtRasentan (SONAR); a new enrichment study design. J Am Soc Nephrol, 25, 2014, 578A.
15. 15 Heerspink, HJ, de Zeeuw, D, The kidney in type 2 diabetes therapy. Rev Diabet Stud 8 (2011), 392–402.